Can Platelet-Rich Plasma (PRP) Regrow Cartilage?

Platelet-rich plasma does not reliably regrow cartilage in human joints, based on the clinical evidence available today. In the lab, PRP clearly stimulates cartilage cells to multiply and produce new matrix material. But when researchers use MRI to measure actual cartilage thickness or volume in patients’ knees after PRP injections, the changes are statistically insignificant. What PRP does do, at least in the short to medium term, is reduce pain and improve joint function for many people with osteoarthritis. The gap between those two findings is the central tension in PRP research, and it matters for anyone considering the treatment.

Why Cartilage Has Such a Hard Time Healing

Cartilage is unusual tissue. Unlike bone or skin, it has no blood vessels and no nerves running through it. That lack of blood supply means cartilage cells get their nutrients almost entirely from joint fluid, which provides limited nourishment. Cartilage cells also divide slowly and migrate poorly, so when damage occurs, there simply are not enough cells arriving at the injury site to mount a meaningful repair response.

This is why a scraped knee heals in days while a worn cartilage surface in a knee joint can deteriorate for years without recovering. The body’s normal wound-healing toolkit, which relies heavily on blood flow to deliver growth factors, immune cells, and raw materials, barely reaches cartilage. PRP therapy attempts to work around this limitation by concentrating growth factors from your own blood and injecting them directly into the joint.

What PRP Does to Cartilage Cells in the Lab

The case for PRP starts with convincing laboratory data. When researchers expose cartilage cells to PRP in a dish, the results are striking. One foundational study found that PRP-treated porcine cartilage cells showed a 115% increase in proteoglycan production and a 163% increase in collagen production compared to standard serum, while the cells remained phenotypically stable and did not change their basic character.¹ More recent work has confirmed that activated PRP promotes proliferation and synthesis of key cartilage proteins in osteoarthritic chondrocytes specifically, not just healthy cells.²

PRP contains a cocktail of growth factors, including TGF-beta, FGF, IGF, and BMP, that are known to drive cell proliferation and cartilage matrix assembly. In a controlled lab environment, these factors clearly push cartilage cells to do more of what they are supposed to do. The problem is that a petri dish is not a joint. Inside a living knee with ongoing mechanical stress, inflammation, and limited nutrient delivery, the biology gets more complicated.

The Disconnect Between Pain Relief and Cartilage Regrowth

Clinical trials of PRP for knee osteoarthritis consistently show two things that seem contradictory until you look closely. PRP reduces pain and improves function scores, often meaningfully. But it does not produce measurable cartilage regrowth on imaging.

A meta-analysis of randomized controlled trials found that PRP produced statistically superior improvements in pain and function scores compared to placebo, exceeding clinically meaningful thresholds at three and six months.³ A separate randomized trial confirmed that patients treated with PRP maintained better scores at 3, 6, and 12 months compared to saline.⁴

But the largest and most rigorous placebo-controlled trial to date, the RESTORE trial published in JAMA, found no significant difference in pain or joint structure at 12 months between PRP and saline placebo injections. Mean pain scores changed by 2.1 points in the PRP group versus 1.8 in the placebo group, a gap that was not statistically significant.⁵ The researchers concluded their findings did not support PRP for managing knee osteoarthritis. This trial looms large over the field because of its rigorous blinding and the fact that it specifically measured cartilage volume on MRI as a structural outcome.

The structural evidence is even more consistently discouraging. A systematic review and meta-analysis pooling data from multiple studies found that PRP treatment was not associated with a significant increase in cartilage thickness or overall cartilage content compared to controls.⁶ An MRI study of patients with moderate osteoarthritis found that while PRP improved pain and function, there was no significant change in articular cartilage as measured by imaging.⁷

A 3D MRI analysis offered a slightly more nuanced picture: some knee regions showed cartilage thickness increases after PRP, but the areas most affected by medial osteoarthritis showed increases in fewer than 20% of treated knees.⁸ In other words, PRP may modestly slow cartilage loss in some spots, but the regions where you actually need it most seem to benefit least.

So where is the pain relief coming from if the cartilage is not regrowing? Most likely from PRP’s anti-inflammatory effects. The growth factors in PRP can suppress inflammatory signaling in the joint, reduce swelling, and improve the biochemical environment around the remaining cartilage. Feeling better and structurally healing are two different things, and PRP appears much better at the former.

How PRP Stacks Up Against Other Injections

Two other injectable treatments are commonly used for knee osteoarthritis: hyaluronic acid (HA), a lubricant that mimics natural joint fluid, and corticosteroids, which are powerful anti-inflammatory drugs. PRP appears to outperform both over time, though the comparisons come with caveats.

Multiple meta-analyses have found PRP superior to HA for long-term pain relief and function improvement.⁹ One systematic review of randomized trials reported that patients receiving PRP showed a 44.7% mean improvement in function scores compared to 12.6% for HA patients, and over half the included pain studies favored PRP at the latest follow-up.¹⁰ That said, some reviewers have cautioned that while PRP appears better for long-term use, there is still insufficient data showing objective structural improvement.¹¹

Against corticosteroids, PRP shows a different pattern. Both relieve pain quickly, with corticosteroids producing slightly faster relief in the first week. But by one year, PRP patients maintained substantially better pain scores: roughly a 52% reduction from baseline for PRP versus 14% for corticosteroids.¹² Corticosteroids also carry concerns about accelerating cartilage breakdown with repeated use, a worry that does not apply to PRP.

PRP Combined with Surgery or Stem Cells

Where PRP may contribute most to actual cartilage regrowth is not as a standalone injection, but as an add-on to surgical or cell-based therapies. This is where the preclinical evidence gets genuinely interesting.

In a sheep model of cartilage defects, PRP combined with microfracture surgery (a technique that creates small holes in exposed bone to stimulate a repair response) showed a positive effect on cartilage repair and restoration compared to microfracture alone.¹³ In a rabbit model, a scaffold infused with platelet-derived material recruited anti-inflammatory immune cells and improved cartilage tissue regeneration.¹⁴

The combination of PRP with mesenchymal stem cells may be where real cartilage regeneration eventually comes from. In a rabbit study, injecting bone marrow stem cells with PRP into full-thickness cartilage defects produced significant increases in chondrocyte numbers, cartilage area, and type 2 collagen, the hallmark protein of healthy articular cartilage.¹⁵ A human comparison is even more telling: when researchers compared stem cells derived from fat tissue against PRP alone for treating cartilage defects during arthroscopy, the stem cell group produced thick, smooth, hyaline-like cartilage comparable to native tissue, while the PRP group produced fibrocartilage, a tougher but inferior repair tissue.¹⁶

That finding captures the current state of PRP and cartilage regeneration well. PRP by itself tends to produce fibrocartilage at best, a functional but structurally imperfect repair. True hyaline cartilage regrowth, the kind that can actually restore a joint surface, likely requires actual progenitor cells, with PRP playing a supporting role as a growth factor delivery system rather than the star of the show.

Who Responds Best to PRP

Not everyone gets the same benefit from PRP, and the severity of your arthritis is one of the strongest predictors. Real-world clinical data from Japan found no significant differences in pain improvement among patients with mild to moderate arthritis (Kellgren-Lawrence grades 1 through 3), but those with the most severe arthritis (grade 4, meaning bone-on-bone) showed significantly less improvement.¹⁷ This makes intuitive sense: if most of your cartilage is already gone and your joint has remodeled significantly, injecting growth factors into the space is unlikely to reverse the damage.

Researchers are now trying to figure out who will respond to PRP before the injection, using machine learning to identify patterns. One model identified osmotic pressure, a blood lipoprotein called Lp(a), and uric acid levels as the clinical factors most strongly associated with treatment response.¹⁸ Another found that baseline mental health scores and pre-treatment knee function scores were the most influential predictors of who would benefit, and that removing mental health measures from the model caused its predictive accuracy to drop to essentially a coin flip.¹⁹

That second finding is worth pausing on. It suggests that psychological factors like mood and mental health significantly influence whether someone reports improvement after PRP. This does not mean the pain relief is “all in your head,” but it does mean that patient-reported outcomes in PRP trials may partly reflect general well-being rather than joint-specific changes. It is another reason to be cautious about interpreting symptom improvement as evidence of structural repair.

The Standardization Problem

One of the most frustrating aspects of PRP research is that “PRP” is not a single product. Different clinics use different preparation methods, and the resulting injections can vary dramatically in platelet concentration, white blood cell content, and growth factor profiles. Studies have noted that PRP preparation methods are highly variable and that published research lacks consistency in reporting how PRP was prepared and characterized.²⁰

This matters because the composition of PRP affects how it works. A rabbit study comparing leukocyte-poor PRP (low in white blood cells) to leukocyte-rich PRP found that the leukocyte-poor version produced significantly lower levels of inflammatory markers in the joint.²¹ Some researchers now argue that total platelet dose, meaning the absolute number of platelets injected rather than their concentration, is a more reliable predictor of therapeutic success.²²

When different trials use different PRP formulations and different injection protocols, comparing their results becomes extremely difficult. A positive result in one study using leukocyte-poor PRP with three injections may not apply to a clinic using leukocyte-rich PRP with a single injection. This variability is probably one reason why meta-analyses sometimes reach different conclusions about whether PRP “works” and partly explains why the RESTORE trial, which used a single injection protocol, may have underperformed relative to studies using multiple injections.

Safety and Side Effects

Because PRP is derived from your own blood, serious adverse events are rare. A systematic review and meta-analysis covering over 1,200 PRP-treated knees found that side effects occurred in about 19% of cases, with mild knee pain and swelling being the most common at roughly 11%. No severe adverse events were reported across any treatment group.²³ The symptoms typically resolve on their own within a few days. Leukocyte-rich formulations tend to cause more post-injection soreness than leukocyte-poor versions, while leukocyte-poor PRP shows a safety profile comparable to hyaluronic acid injections.

There is no evidence of PRP causing tumor growth, autoimmune reactions, or joint infections at higher rates than other injectable therapies. The main risk is financial: you pay for a treatment that might not work, especially if your arthritis is already advanced.

Cost, Insurance, and the Regulatory Landscape

PRP is not FDA-approved for any specific orthopedic indication. It can legally be offered “off-label” in the United States, and clinics do so widely. A single treatment typically costs between $500 and $2,500, and most insurance plans do not cover it. Patients often return for multiple treatments, compounding the expense.²⁴

The distinction between FDA “clearance” and “approval” is relevant here. The devices used to prepare PRP are FDA-cleared, meaning they are deemed safe for producing the product. But the PRP itself has not gone through the clinical trial process required for FDA approval for treating osteoarthritis. Experts have recommended that clinicians inform patients of this distinction when offering PRP off-label, given the cost and the mixed clinical evidence.²⁴

This creates a tricky situation for patients. Many orthopedic and sports medicine clinics market PRP aggressively, sometimes with language implying it can regenerate cartilage. The marketing often draws on the laboratory data showing chondrocyte stimulation, or on the symptom-improvement trials, without clearly distinguishing those from structural regeneration evidence. If you are considering PRP, the honest framing is that it may help with pain for months, but you should not expect your cartilage to grow back.

When PRP Might Make Sense Anyway

Despite the lack of cartilage regrowth evidence, PRP occupies a reasonable spot in the treatment ladder for mild to moderate knee osteoarthritis. If you have tried physical therapy, activity modification, and over-the-counter pain relief without adequate improvement, PRP offers a chance at meaningful pain relief with minimal risk. Its track record against hyaluronic acid and corticosteroids suggests it performs at least as well and potentially better over six to twelve months, without the concerns about cartilage degradation that come with repeated steroid injections.

The patients who should probably avoid it, or at least have tempered expectations, are those with severe bone-on-bone arthritis. At that stage, the evidence suggests PRP provides significantly less benefit, and the money may be better put toward other options. For younger patients with focal cartilage injuries rather than widespread arthritis, PRP may play a more useful role as a complement to surgical repair techniques rather than as a standalone treatment.

Fibrocartilage Versus Hyaline Cartilage

Even in the most optimistic scenarios where PRP contributes to some tissue formation at a damaged site, the repair tissue tends to be fibrocartilage rather than true hyaline cartilage. These are meaningfully different materials. Hyaline cartilage is the smooth, glassy tissue that lines healthy joint surfaces. It is optimized for low-friction, load-bearing movement and can last decades under normal use. Fibrocartilage is denser and more fibrous, better suited for absorbing shock in places like the meniscus or the discs between vertebrae. On a joint surface, fibrocartilage functions acceptably in the short term but wears down faster than hyaline cartilage under the repetitive forces of walking, running, and bending.

The human study comparing stem cells to PRP for arthroscopic cartilage repair captured this difference directly: stem cells produced hyaline-like tissue with normal mineralization, while PRP produced fibrocartilage with abnormal mineralization.¹⁶ This is probably PRP’s ceiling when used alone: it can encourage tissue formation, but the tissue it encourages is not the tissue you started with. For the field of cartilage regeneration, the real frontier is not PRP by itself but PRP combined with cell-based therapies or bioengineered scaffolds that can guide proper tissue formation in ways that growth factors alone cannot.